Moving MRD from a Prognostic Signal to a Decision-Making Diagnostic: Lessons from Bladder Cancer
11:30 am - Thursday 18th March 2027
- Breaking down the MRD label into distinct intended uses, and why each demands a different level of proof
- Defining the clinical decision points where MRD results change what happens to the patient
- Applying that framework to bladder cancer, including early learnings from a urinebased MRD application
- Assessing what regulators will need to see before MRD-guided decisions become standard of care, and what the first companion diagnostic signals for the field
